GRANT PROGRESS REPORT SUMMARY

Grant: 01609: Probiotic VSL# 3 Reduces Enteritis in Dogs with Inflammatory Bowel Disease

Principal Investigator: Dr. Albert E. Jergens, DVM, PhD
Research Institution: Iowa State University
Grant Amount: $97,416.00
Start Date: 1/1/2012  End Date: 12/31/2014
Progress Report: End-Year 1
Report Due: 12/31/2012  Report Received: 4/4/2013

Recommended for Approval: Approved

(Content of this report is not confidential. A grant sponsor’s CHF Health Liaison may request the confidential scientific report submitted by the investigator by contacting the CHF office. The below Report to Grant Sponsors from Investigator can be used in communications with your club members.)

Original Project Description:

Idiopathic inflammatory bowel disease (IBD) is a common cause of chronic gastrointestinal disease in dogs. Accumulating evidence in human IBD and animal models suggests that imbalances in composition of the intestinal microbiota contribute to the pathogenesis of chronic intestinal inflammation. Recent studies have also shown that dogs with IBD have distinctly different duodenal microbial communities compared to healthy dogs. Current treatments for IBD include the administration of nonspecific anti-inflammatory drugs which may confer serious side effects and do not address the underlying basis for disease, namely, altered microbial composition. Use of probiotics (viable, non-pathogenic bacteria that exert health benefits beyond basic nutrition) offers an attractive, physiologic, and non-toxic alternative to shift the balance to protective species and treat IBD. The aim of the proposed study is to investigate the clinical, microbiologic, and anti-inflammatory effects of probiotic VSL#3 in the treatment of canine IBD. We hypothesize that VSL#3 used as an adjunct to standard therapy (i.e., elimination diet and prednisone) will induce a beneficial alteration of enteric bacteria leading to induction and maintenance of remission in dogs with IBD. A randomized, controlled clinical trial of 8 weeks duration will assess the efficacy of standard therapy + probiotic versus standard therapy alone. There is a need for additional data to be generated to provide proof of efficacy in probiotic therapy before these agents can be applied to widespread clinical use. These studies will also provide highly relevant insight into the anti-inflammatory effects of probiotics for treatment of human and canine IBD.
Grant Objectives:

To determine the clinical, microbiologic, and anti-inflammatory effects of probiotic VSL #3 in the treatment of canine IBD.

Publications:


Report to Grant Sponsor from Investigator:

Idiopathic inflammatory bowel disease (IBD) is a common cause of chronic gastrointestinal disease in dogs. Accumulating evidence in human IBD and animal models suggests that imbalances in composition of the intestinal microbiota contribute to the pathogenesis of chronic intestinal inflammation. Recent studies in dogs with IBD have shown that they have distinctly different duodenal microbial communities compared to healthy dogs. Current treatments for IBD include the administration of nonspecific anti-inflammatory drugs which may confer serious side effects and do not address the underlying basis for disease, namely, altered microbial composition. Use of probiotics (viable, non-pathogenic bacteria that exert health benefits beyond basic nutrition) offers an attractive, physiologic, and non-toxic alternative to shift the balance to protective species and treat IBD. The aim of the proposed study is to investigate the clinical, microbiologic, and anti-inflammatory effects of probiotic VSL#3 in the treatment of canine IBD. We hypothesize that VSL#3 used as an adjunct to standard therapy (i.e., elimination diet and prednisone) will induce a beneficial alteration of enteric bacteria leading to induction and maintenance of remission in dogs with IBD. A randomized, controlled clinical trial of 8 weeks duration is presently being performed to assess the efficacy of standard therapy + probiotic versus standard therapy alone.

Our data to date suggests that dogs treated with VSL#3 do respond favorably to the probiotic as evidenced by a reduction in their clinical disease severity. What remains unclear (ie, the clinicians are blinded as to whether a dog receives VSL#3 or placebo) is whether remission occurs more quickly in VSL#3-treated dogs vs placebo-medicated dogs. There is a need for additional data to be generated to provide proof of efficacy in probiotic therapy before these agents can be applied to widespread clinical use. These studies will also provide highly relevant insight into the anti-inflammatory effects of probiotics for treatment of human and canine IBD. We have produced 2 research abstracts to date with data from these studies.

We are actively seeking additional dogs for inclusion into the trial at this time, and would particularly welcome purebred dogs at increased risk for IBD including GSD, boxer, and French Bull dog breeds.